Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 50: 120-124, 2004. First published November 18, 2003; 10.1373/clinchem.2003.026179
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2003.026179v1
clinchem.2003.026179v2
50/1/120    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (21)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martí, R.
Right arrow Articles by Hirano, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martí, R.
Right arrow Articles by Hirano, M.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Evidence Based Laboratory Medicine and Test Utilization
(Clinical Chemistry. 2004;50:120-124.)
© 2004 American Association for Clinical Chemistry, Inc.

Evidence-based Laboratory Medicine and Test Utilization

Definitive Diagnosis of Mitochondrial Neurogastrointestinal Encephalomyopathy by Biochemical Assays

Ramon Martí1,2, Antonella Spinazzola1,3, Saba Tadesse1, Ichizo Nishino1,4, Yutaka Nishigaki1,4 and Michio Hirano1,a

1 Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY.
2 Centre d’Investigacions en Bioquímica i Biologia Molecular, Hospital Universitari Vall d’Hebron, Barcelona, Spain.
3 Division of Molecular Neurogenetics, National Neurological Institute "Carlo Besta", Milan, Italy.
4 Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.

aAddress correspondence to this author at: Department of Neurology, Columbia University College of Physicians and Surgeons, P&S 4-443, 630 West 168th St., New York, NY 10032. Fax 212-305-3986; e-mail mh29{at}columbia.edu.

Background: Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is caused by mutations in the gene encoding thymidine phosphorylase (TP). The clinical manifestations of MNGIE are recognizable and homogeneous, but in the early stages, the disease is often misdiagnosed. This study assesses the reliability of biochemical assays to diagnose MNGIE.

Methods: We studied 180 patients with clinical features suggestive of MNGIE, 14 asymptomatic TP mutation carriers, and 20 controls. TP enzyme activity in the buffy coat was determined by a fixed-time method, and the plasma nucleosides thymidine (dThd) and deoxyuridine (dUrd) were assessed by a gradient-elution reversed phase HPLC method. TP was sequenced through standard procedures in patients who met the clinical criteria for MNGIE.

Results:Twenty-five of the 180 patients fulfilled the clinical criteria for MNGIE and had homozygous or compound heterozygous TP mutations. All had drastically decreased TP activity [mean (SD), 10 (15) nmol thymine formed · h-1 · (mg protein)-1 vs 634 (217) nmol thymine formed · h-1 · (mg protein)-1 for the controls]. Relative to the control mean, TP activities were reduced to 35% in mutation carriers and 65% in MNGIE-like patients. All 25 MNGIE patients had detectable plasma dThd [8.6 (3.4) µmol/L] and dUrd [14.2 (4.4) µmol/L]. Controls, carriers, and MNGIE-like patients showed no detectable plasma dThd and dUrd.

Conclusions:We propose a diagnostic algorithm based on the determination of plasma dThd and dUrd, TP activity in buffy coat, or both to make a definitive diagnosis of MNGIE. Increased concentrations of dThd (>3 µmol/L) and dUrd (>5 µmol/L) in plasma or a decrease in buffy coat TP activity to <=8% relative to controls is sufficient to diagnose MNGIE.




The following articles in journals at HighWire Press have cited this article:


Home page
 Hum Mol GenetHome page
L. C. Lopez, H. O. Akman, A. Garcia-Cazorla, B. Dorado, R. Marti, I. Nishino, S. Tadesse, G. Pizzorno, D. Shungu, E. Bonilla, et al.
Unbalanced deoxynucleotide pools cause mitochondrial DNA instability in thymidine phosphorylase-deficient mice
Hum. Mol. Genet., February 15, 2009; 18(4): 714 - 722.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
S. Rahman and J. Poulton
Diagnosis of mitochondrial DNA depletion syndromes
Arch. Dis. Child., January 1, 2009; 94(1): 3 - 5.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Rampazzo, S. Fabris, E. Franzolin, K. Crovatto, M. Frangini, and V. Bianchi
Mitochondrial Thymidine Kinase and the Enzymatic Network Regulating Thymidine Triphosphate Pools in Cultured Human Cells
J. Biol. Chem., November 30, 2007; 282(48): 34758 - 34769.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. F. Chinnery and J. Vissing
Treating MNGIE: Is reducing blood nucleosides the first cure for a mitochondrial disorder?
Neurology, October 24, 2006; 67(8): 1330 - 1332.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.